| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Regulatory Decision example | NDA | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Regulatory Decision example | NDA | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Regulatory Decision example | NDA | — | Subscribe to access the data. | Peptides | Endocrine System |
Recent Updates
Recently added Catalysts
Rhythm Pharmaceuticals, Inc.$107.56
+1.43 (+1.35%)
B 65Pipeline Score Overvalued Pharma · Commercial
Market Cap
6.02 B
EPS
-3.14
P/E Ratio
-
Value Trade
35.22 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
60.11 M
R&D Expenses
41.73 M
Operating CF
-44.19 M
Total Assets
442.32 M
Total Liabilities
204.70 M
Equity
122.91 M
D/E Ratio
12,345
-4.74 %
Week
2.83 %
1 Month
-14.68 %
3 Month
-12.92 %
6 Month
305.73 %
5 Year
278.46 %
All Time
Cash Data
Cash Position
340.63 M
Monthly Burn
14.73 M
Runway
20.3 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
21.42 K
52 Week Range
58.71 - 122.20
% held by Insiders
3.19 %
% held by Institutions
106.03 %
Enterprise Value
5.91 B
Total Shares
68.53 M
Short %
15.66 %
Float Shares
61.13 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rhythm Pharmaceuticals, Inc.
490Total events
5Upcoming
142Tier-1 (high impact)
2017 – 2026Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2Trial Completion
Subscribe to view catalyst details
Event history 2
TBD
▲Full ResultsSetmelanotideApprovedClinical Data
Subscribe to view catalyst details
TBD
▲PublicationSetmelanotideApprovedPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | setmelanotide (IMCIVREE) | Phase 2 data readout | Phase 2 | — | – | – | – |
2026-06-30 | setmelanotide (IMCIVREE) | Phase 2 data readout | Phase 2 | — | – | – | – |
2026-06-30 | setmelanotide (IMCIVREE) | Phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
B65
Pipeline Score $3.7B
Pipeline ValueOvervalued
Valuation Signal8
Drugs Scored0.6x
rNPV / MCap Top 93%
Small Cap (rank 65 of 913)
Percentile RankRhythm Pharmaceuticals, Inc. holds a solid B-grade pipeline (65/100), with $5.8B risk-adjusted pipeline value, led by Setmelanotide in Obesity (Phase 3), across $121B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Setmelanotide Small molecule | Hypothalamic Obesity | Phase 3 | NCT05774756 | 74% | $2.6B | ACTIVE NOT_RECRUITING | 200 | SLOW | B (66) | Apr 16, 2027 | LOW_RISK | LOW May 29, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
setmelanotide PriorityOrphan | acquired hypothalamic obesity | Phase 3 | 2026-07-08 | -19.8% placebo-adjusted difference in body mass index (BMI) reduction (n=120); -16.5% mean BMI reduction from baseline for all patients on setmelanotide therapy (n=81) compared with +3.3% BMI change for patients on placebo (n=39) at 52 weeks (p<0.0001); 80% of patients on setmelanotide achieved BMI reduction of 5% or greater at 52 weeks Read More | Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity Read More | |
setmelanotide PriorityOrphan | acquired hypothalamic obesity | Phase 3 | 2026-07-08 | -19.8% placebo-adjusted difference in body mass index (BMI) reduction (n=120); -16.5% mean BMI reduction from baseline for all patients on setmelanotide therapy (n=81) compared with +3.3% BMI change for patients on placebo (n=39) at 52 weeks (p<0.0001); 80% of patients on setmelanotide achieved BMI reduction of 5% or greater at 52 weeks Read More | Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity Read More | |
setmelanotide PriorityOrphan | acquired hypothalamic obesity | Phase 3 | 2026-07-08 | -19.8% placebo-adjusted difference in body mass index (BMI) reduction (n=120); -16.5% mean BMI reduction from baseline for all patients on setmelanotide therapy (n=81) compared with +3.3% BMI change for patients on placebo (n=39) at 52 weeks (p<0.0001); 80% of patients on setmelanotide achieved BMI reduction of 5% or greater at 52 weeks Read More | Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RYTM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RYTM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RYTMRhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Rhythm Pharmaceuticals will host a live conference call on August 4, 2026, to report its second quarter financial results and provide a corporate update. The company focuses on rare neuroendocrine diseases and has received FDA and European Commission approvals for its lead product, setmelanotide. The call will be accessible via their website, with an archived version available for 30 days.
Read more →RYTMRhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced the publication of Phase 3 TRANSCEND trial results in The New England Journal of Medicine. The trial demonstrated significant weight loss and hunger reduction in patients with acquired hypothalamic obesity treated with setmelanotide. The FDA has approved setmelanotide as the first therapy for this condition, highlighting its potential impact on patient care.
Read more →RYTMRhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
Rhythm Pharmaceuticals presented new data at ENDO 2026, showcasing the effectiveness of MC4R agonists, particularly setmelanotide and bivamelagon, in treating acquired hypothalamic obesity (HO), Bardet-Biedl syndrome (BBS), and Prader-Willi syndrome (PWS). The data revealed significant weight loss and improvements in hunger measures, with a focus on long-term efficacy and real-world outcomes. However, some adverse events were reported, including nausea and hypersensitivity reactions.
Read more →RYTMRhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
Read more →RYTMRhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
Rhythm Pharmaceuticals will announce interim results from its Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome on June 13, 2026. The conference call will feature insights from company executives and a pediatric endocrinologist. Setmelanotide is already approved for certain obesity-related conditions, highlighting its potential impact on rare diseases.
Read more →RYTM▼ -5%on this news
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
Rhythm Pharmaceuticals announced that seven abstracts, including four late-breaking ones, have been accepted for presentation at ENDO 2026, scheduled for June 13-16, 2026. Key presentations will focus on the efficacy of setmelanotide in treating Prader-Willi syndrome and acquired hypothalamic obesity. The company will also host its inaugural MOMENTUM meeting to discuss advancements in MC4R pathway diseases.
Read more →RYTMRhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
Rhythm Pharmaceuticals announced the publication of a new diagnostic algorithm for Bardet-Biedl syndrome (BBS) in the American Journal of Medical Genetics. This evidence-based algorithm aims to simplify and expedite the diagnosis of BBS, integrating advances in genetic testing and clinical understanding. It is designed to assist healthcare practitioners in making timely diagnoses across various clinical presentations.
Read more →RYTMrhythm pharmaceuticals announces participation in upcoming investor conferences
rhythm pharmaceuticals announces participation in upcoming investor conferences
Read more →RYTMRhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
Rhythm Pharmaceuticals announced the presentation of new data on setmelanotide at the 2026 European Congress of Endocrinology, highlighting its effectiveness for treating acquired hypothalamic obesity. Real-world data showed significant BMI reductions in patients, along with improvements in cardiometabolic risk factors. Additionally, research underscored the issue of underreporting hyperphagia severity in affected individuals. Overall, the findings support setmelanotide's role as a therapeutic option for patients with this rare neuroendocrine condition.
Read more →RYTMRhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
Rhythm Pharmaceuticals announced that its CEO, Dr. David Meeker, will participate in a fireside chat at the Bank of America Global Healthcare Conference on May 13, 2026. The event will be webcasted, allowing broader access to the discussion. Rhythm is dedicated to addressing rare neuroendocrine diseases and has received FDA and European approvals for its lead product, setmelanotide.
Read more →RYTM▲ +7.9%on this newsshared move
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
Rhythm Pharmaceuticals reported a strong start for IMCIVREE, generating $60.1 million in revenue in Q1 2026. The drug received FDA approval for acquired hypothalamic obesity, with over 150 patient start forms submitted in the first six weeks. The European Commission also granted Marketing Authorization, with launches anticipated in 2027. However, the company reported a net loss of $56.7 million and faced challenges in U.S. revenue due to inventory issues.
Read more →RYTMRhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
Rhythm Pharmaceuticals presented new data on setmelanotide's long-term efficacy in treating pediatric patients with acquired hypothalamic obesity at the Pediatric Endocrine Society Annual Meeting. After 2.5 years of treatment, patients showed significant reductions in BMI and improvements in weight categories. The safety profile remains consistent with previous reports, although some adverse events were noted.
Read more →RYTMRhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced that the European Commission has granted marketing authorization for IMCIVREE® (setmelanotide) for treating obesity and controlling hunger in patients aged 4 and above with acquired hypothalamic obesity. This marks the first approved therapy for this condition in Europe, following successful results from the Phase 3 TRANSCEND trial. The company aims to facilitate patient access to this treatment across Europe, with commercial launches anticipated in 2027.
Read more →RYTMRhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
Rhythm Pharmaceuticals will report its first quarter 2026 financial results on May 5, 2026, during a live conference call. Additionally, CFO Hunter Smith will participate in a fireside chat at the Needham Virtual Healthcare Conference on April 16, 2026. Both events will be available via webcast on the company's website.
Read more →RYTMRhythm Pharmaceuticals Announces Changes to Board of Directors
Rhythm Pharmaceuticals has appointed Kim Popovits to its Board of Directors, replacing Ed Mathers. Popovits brings over 40 years of experience in the life sciences sector, having held leadership roles at Genomic Health and Genentech. Her expertise is expected to support Rhythm's mission in treating rare neuroendocrine diseases and advancing its product pipeline.
Read more →RYTMRhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Rhythm Pharmaceuticals received a positive opinion from the CHMP to expand IMCIVREE's marketing authorization for treating obesity and controlling hunger in patients with acquired hypothalamic obesity. This follows a recent FDA approval, highlighting the drug's potential to address a significant unmet medical need. The European Commission is expected to make a final decision by Q2 2026.
Read more →RYTMRhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals has received FDA approval for IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity, a rare condition leading to significant weight gain due to hypothalamic dysfunction. This approval marks the first therapy available for this condition, following positive results from the Phase 3 TRANSCEND trial, which showed a significant reduction in BMI. IMCIVREE will be available immediately to patients aged 4 and older in the U.S.
Read more →RYTMPANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)
PANTHERx Rare Pharmacy has been chosen by Rhythm Pharmaceuticals as the exclusive U.S. specialty pharmacy for the expanded indication of IMCIVREE (setmelanotide) for treating acquired hypothalamic obesity in patients aged 4 and older. This partnership aims to improve patient access and support through PANTHERx's RxARECARE model, which provides personalized care and financial navigation. The expanded indication represents a significant advancement in treatment options for this rare disease.
Read more →RYTMRhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial -- Four substudies did not meet pre-specified primary endpoints -- -- Post hoc analyses show setmelanotide achieved statistically significant BM
Rhythm Pharmaceuticals has announced the topline results from its Phase 3 EMANATE trial, where four substudies did not meet their pre-specified primary endpoints. However, post hoc analyses revealed that setmelanotide achieved significant BMI reductions in specific patient groups with genetically-driven obesity. The company aims to further evaluate the data to explore clinical development paths for its treatments. A conference call is scheduled to discuss these findings in detail.
Read more →RYTMRhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced additional positive data from its Phase 3 TRANSCEND trial of setmelanotide for acquired hypothalamic obesity. The trial showed an 18.8% placebo-adjusted difference in BMI reduction at 52 weeks across 142 patients. The company is preparing for a supplemental New Drug Application with a PDUFA goal date of March 20, 2026, and is also seeking approvals in Europe and Japan.
Read more →RYTMRhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Rhythm Pharmaceuticals reported a strong financial performance for Q4 and full year 2025, with net product revenues of $57.3 million for the quarter and $194.8 million for the year. The company is preparing for a PDUFA goal date on March 20, 2026, for setmelanotide's sNDA in acquired hypothalamic obesity. Additionally, they are on track to report topline data from Phase 3 trials for both setmelanotide and bivamelagon in March 2026.
Read more →RYTMRhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhythm Pharmaceuticals will host a live conference call on February 26, 2026, to report its fourth quarter and full year 2025 financial results. The company will also provide a corporate update during the call. Additionally, CEO David Meeker will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026.
Read more →RYTMRhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
Rhythm Pharmaceuticals announced that CFO Hunter C. Smith will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11. The event will be webcasted and available for replay on the company's website. Rhythm continues to focus on treatments for rare neuroendocrine diseases, with its lead asset, setmelanotide, already approved in the U.S. and Europe.
Read more →RYTMRhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
Rhythm Pharmaceuticals reported preliminary net product revenues of approximately $57 million for Q4 2025, marking an 11% increase from Q3 2025. For FY 2025, revenues are expected to reach $194 million, a 50% increase from FY 2024. The company anticipates key milestones in 2026, including data from Phase 3 trials for setmelanotide in acquired hypothalamic obesity and genetically caused MC4R pathway diseases.
Read more →RYTM▲ +12.3%on this news
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
Rhythm Pharmaceuticals announced positive preliminary results from its exploratory Phase 2 trial of setmelanotide for Prader-Willi syndrome (PWS). The drug demonstrated reductions in BMI and hyperphagia in patients at 3 and 6 months. The company plans to move forward with a Phase 3 registrational trial, pending successful completion of this study. Additionally, a new Phase 1 study for the MC4R agonist RM-718 has been initiated.
Read more →RYTM▲ +12.3%on this newsshared move
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
Rhythm Pharmaceuticals will announce preliminary data from its exploratory Phase 2 trial of setmelanotide for Prader-Willi syndrome on December 11, 2025. The company aims to provide insights into the drug's efficacy and safety for patients with this rare condition. A live conference call and webcast will be held to discuss the findings.
Read more →RYTMRhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
Rhythm Pharmaceuticals presented four datasets at ObesityWeek 2025, highlighting the efficacy of setmelanotide in treating acquired hypothalamic obesity. The Phase 3 TRANSCEND trial data demonstrated significant BMI reductions and improvements in cardiometabolic health for patients receiving concomitant GLP-1 therapy. Presentations included patient experiences and detailed analyses of health outcomes, showcasing the potential of setmelanotide to transform patient lives.
Read more →RYTMRhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced that the FDA has extended the review period for IMCIVREE® (setmelanotide) by three months, with a new PDUFA goal date set for March 20, 2026. The extension follows the FDA's request for additional sensitivity analyses of clinical efficacy data from the Phase 3 trial. CEO David Meeker expressed confidence in the product's potential to benefit patients with acquired hypothalamic obesity.
Read more →RYTMRhythm Pharmaceuticals annonce le remboursement public de l'IMCIVREE® (setmélanotide) au Canada dans cinq provinces et dans le cadre du Programme fédéral des services de santé non assurés
Rhythm Pharmaceuticals has announced public reimbursement for IMCIVREE (setmelanotide) in five Canadian provinces and through the federal Non-Insured Health Benefits program. This decision enhances access to treatment for eligible patients aged 6 and older suffering from Bardet-Biedl syndrome and clinically or genetically confirmed obesity. The approval marks a significant step in addressing the challenges faced by these patients.
Read more →RYTMRhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
Rhythm Pharmaceuticals has secured public reimbursement for IMCIVREE (setmelanotide) in five Canadian provinces and under the Federal Non-Insured Health Benefits Program. This decision allows eligible patients aged 6 and older with Bardet-Biedl syndrome and obesity to access treatment. The approval follows Health Canada's priority review and highlights the government's commitment to addressing rare diseases.
Read more →RYTM▼ -7.7%on this newsshared move
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
Rhythm Pharmaceuticals reported a third quarter 2025 net product revenue of $51.3 million from IMCIVREE, reflecting a 6% increase from the previous quarter. The FDA has set a PDUFA goal date of December 20, 2025, for the supplemental NDA for setmelanotide in acquired hypothalamic obesity. The company also anticipates preliminary results from a Phase 2 trial in Prader-Willi syndrome by the end of 2025.
Read more →RYTMRhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Rhythm Pharmaceuticals, Inc. announced it will report its third quarter 2025 financial results on November 4, 2025. In addition, two fireside chats featuring key executives will take place on November 12, 2025, at significant healthcare conferences in Boston and New York. Rhythm's lead asset, IMCIVREE, continues to be a focal point in their commitment to treat rare neuroendocrine diseases, with regulatory approvals in the U.S. and Europe. The company aims to provide updates on its financial performance and ongoing clinical programs during these events.
Read more →RYTMRhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Rhythm Pharmaceuticals announced that CEO David Meeker will participate in fireside chats at two upcoming investor conferences. These events will be webcasted and available for replay on the company's website. Rhythm is focused on treating rare neuroendocrine diseases with its lead asset, setmelanotide, which has received FDA and European approvals.
Read more →RYTMRhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced that the FDA has accepted its supplemental New Drug Application for setmelanotide, targeting acquired hypothalamic obesity, with a PDUFA goal date set for December 20, 2025. The EMA has also validated a Type II variation submission for the same indication. The acceptance follows positive results from the Phase 3 TRANSCEND trial, which demonstrated significant reductions in body mass index among participants. Rhythm plans to host an event to discuss commercial readiness for this condition.
Read more →RYTMRhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update -- Second quarter 2025 net product revenue from global sales of IMCIVREE (setmelanotide) of $48.5 million -- -- U.S. and EU regulat
Rhythm Pharmaceuticals reported its financial results for the second quarter of 2025, highlighting net product revenue from IMCIVREE of $48.5 million. The company is on track with U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity and announced positive results from the Phase 2 trial of Bivamelagon. Despite the revenue growth, Rhythm experienced a net loss of $48 million, an increase from the previous year, alongside rising research and development expenses. The company aims to continue expanding its product offerings and commercial initiatives in the latter half of 2025.
Read more →RYTMRhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
Rhythm Pharmaceuticals will report its second quarter 2025 financial results on August 5, 2025, during a live conference call. The company will also participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025. Rhythm is focused on treating rare neuroendocrine diseases and has an ongoing clinical development program for its lead asset, setmelanotide.
Read more →RYTMRhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
Read more →RYTMRhythm Pharmaceuticals Inc Announces Pricing of Upsized Public Offering of Common Stock
Rhythm Pharmaceuticals Inc Announces Pricing of Upsized Public Offering of Common Stock
Read more →RYTM▲ +36.6%on this newsshared move
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity -- Bivamelagon
Rhythm Pharmaceuticals announced positive results from its Phase 2 trial for bivamelagon, an oral MC4R agonist targeting acquired hypothalamic obesity. In the trial, significant BMI reductions were observed, with reductions of -9.3% and -7.7% in the 600mg and 400mg cohorts, respectively. The drug also showed a reduction in hunger scores and is expected to progress towards Phase 3 clinical trials with regulatory input. Despite some reports of adverse events, primarily mild, the overall results indicate promising treatment potential.
Read more →RYTM▲ +36.6%on this newsshared move
Rhythm Pharmaceuticals Inc Announces Proposed Public Offering of Common Stock
Rhythm Pharmaceuticals Inc Announces Proposed Public Offering of Common Stock
Read more →RYTMRhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity
Read more →RYTMRhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025
Rhythm Pharmaceuticals announced that three late-breaking abstracts have been accepted for presentation at the ENDO 2025 conference. Notable presentations include results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide for acquired hypothalamic obesity. Experts from esteemed institutions will present various data, including qualitative insights from patients and results from a Phase 2 trial of bivamelagon. This highlights Rhythm's ongoing commitment to addressing rare neuroendocrine diseases.
Read more →RYTMRhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity N 35 Treated with Setmelanotide for up to Nine Months in French
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity N 35 Treated with Setmelanotide for up to Nine Months in French
Read more →RYTMRhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update -- First quarter 2025 net product revenue from global sales of IMCIVREE (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal
Rhythm Pharmaceuticals reported strong financial results for the first quarter of 2025, with IMCIVREE generating $37.7 million in net product revenue, marking a notable increase from the previous year. The company's pivotal Phase 3 TRANSCEND trial for setmelanotide met its primary endpoint, and regulatory submissions for the treatment in acquired hypothalamic obesity are on track for completion later this year. Despite a net loss of $50.8 million, Rhythm maintains a solid cash position sufficient to fund its operations into 2027, supporting ongoing and future clinical trials.
Read more →RYTMRhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
Rhythm Pharmaceuticals, Inc. has announced that it will report its first quarter 2025 financial results in a conference call on May 7, 2025. The event will be accessible via a live webcast, where the company will also provide a corporate update. Rhythm focuses on treating rare neuroendocrine diseases and is known for its lead asset setmelanotide, which has gained multiple regulatory approvals. This call will serve as a platform for investors and stakeholders to gain insights into the company's financial performance and strategic direction.
Read more →RYTM▲ +17.1%on this news
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity -- Patients with acquired hypothal
Rhythm Pharmaceuticals announced that its pivotal Phase 3 TRANSCEND trial for setmelanotide, aimed at treating acquired hypothalamic obesity, achieved its primary endpoint, demonstrating a statistically significant reduction in body mass index (BMI) among patients. The trial showed a placebo-adjusted BMI reduction of -19.8% after 52 weeks, with significant results in both adults and children. No new safety signals were reported, reinforcing the drug's safety profile. The company plans to submit regulatory applications in the U.S. and EU by the third quarter of 2025.
Read more →RYTM▲ +17.1%on this newsshared move
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
Read more →RYTMRhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE (setmelanotide) in China with Termination of Agreement with RareStone Ltd. BOSTON
Rhythm Pharmaceuticals has recently announced the reacquisition of licensing rights for IMCIVREE (setmelanotide) in China after terminating its agreement with RareStone Group Ltd. This strategic move allows Rhythm to have full control over the treatment for patients with rare neuroendocrine diseases. The company is actively working on global clinical trials for setmelanotide, with topline data expected in the second quarter of 2025. As part of the deal, Rhythm will pay $6.3 million to RareStone and will return previously acquired shares.
Read more →RYTM▲ +5.6%on this newsshared move
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Read more →RYTMRhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration
Rhythm Pharmaceuticals has partnered with the Raymond A. Wood Foundation to conduct research focused on fatigue experienced by individuals with craniopharyngioma. This collaboration aims to gather insights directly from patients and caregivers to enhance understanding of the condition and improve care outcomes. Participation is open to those diagnosed with craniopharyngioma and their caregivers through a dedicated registry. Both organizations are committed to advancing research and advocating for the needs of patients affected by this rare disease.
Read more →RYTMRhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update -- Fourth quarter 2024 net revenue from global sales of IMCIVREE (setmelanotide) of $41.8 million -- -- On track to r
Rhythm Pharmaceuticals reported its Q4 2024 financial results, highlighting net revenue growth from IMCIVREE, which reached $41.8 million. The FDA has approved an expanded label for IMCIVREE to include pediatric patients aged 2 years and older. The company raised approximately $75 million through its equity program, extending its cash runway into 2027. Despite these positive developments, Rhythm also reported a net loss of $44.6 million in Q4 2024 and increased research and administrative expenses compared to the previous year.
Read more →RYTMRhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025
Rhythm Pharmaceuticals has announced that it will report its fourth quarter and full year 2024 financial results on February 26, 2025, along with a corporate update. The company will also host a live conference call and participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on March 3, 2025. Rhythm Pharmaceuticals focuses on transforming the lives of patients with rare neuroendocrine diseases, emphasizing the importance of their lead asset, setmelanotide, in addressing obesity in specific genetic conditions.
Read more →RYTMRhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February
Rhythm Pharmaceuticals, Inc. announced that its CEO, David Meeker, will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference scheduled for February 12, 2025. This event aims to highlight the company’s commitment to transforming the lives of patients with rare neuroendocrine diseases. The chat will be webcasted and accessible on their website, providing an opportunity for stakeholders to engage with the company's developments and initiatives.
Read more →RYTMRhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones -- Preliminary unaudited net revenues from global sales of IMCIVREE (setm
Rhythm Pharmaceuticals has announced preliminary unaudited net revenues from global sales of IMCIVREE, estimating approximately $42 million for Q4 2024 and $130 million for the full year. The company is advancing its clinical pipeline, achieving enrollment milestones in various trials and preparing for a Phase 2 trial in Prader-Willi syndrome. Despite the positive revenue outlook and development progress, the financial results are preliminary and subject to rigorous auditing processes. Rhythm aims to capitalize on its achievements in the rare disease market as it moves into 2025.
Read more →RYTMRhythm Pharmaceuticals Announces FDA Approval of IMCIVREE setmelanotide for Patients as Young as 2 Years Old
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE setmelanotide for Patients as Young as 2 Years Old
Read more →RYTMRhythm Pharmaceuticals Announces ▼ IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old
Rhythm Pharmaceuticals announced that the UK's MHRA has expanded marketing authorization for IMCIVREE to treat obesity in children as young as 2 years old with specific genetic conditions. This decision allows for earlier intervention, thereby potentially improving health outcomes for affected children. IMCIVREE's previous authorization included patients aged 6 years and older, and the updated approval is seen as a significant milestone for these patients and their families. The expanded indication comes as Rhythm aims to address critical needs in rare genetic diseases associated with obesity.
Read more →RYTMRhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
Rhythm Pharmaceuticals presented promising real-world data at the ESPE 2024, showing that four pediatric patients with hypothalamic obesity achieved significant weight reductions after three months on setmelanotide therapy. The company plans to initiate a new substudy evaluating the treatment's efficacy in patients with congenital hypothalamic obesity. All patients involved in the early-access program reported no new safety issues, reinforcing the potential for setmelanotide as a targeted therapy. The presentations at the conference included additional insights on the treatment of rare obesity-related conditions.
Read more →RYTM▼ -6.2%on this newsshared move
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals has announced the granting of inducement restricted stock units (RSUs) to three new employees as part of its employment inducement plan adopted in 2022. A total of 15,750 shares of common stock will be distributed as part of this grant, with a four-year vesting schedule. This move reflects the company's strategy to strengthen its workforce while emphasizing its focus on transforming the lives of patients with rare neuroendocrine diseases. Rhythm is known for its lead product, setmelanotide, which addresses severe obesity related to specific genetic conditions.
Read more →RYTM▼ -6.2%on this newsshared move
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes Endocrinology
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes Endocrinology
Read more →RYTM▲ +6.2%on this news· ran to +27% by day 3shared move
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update -- Third quarter 2024 net revenue from global sales of IMCIVREE (setmelanotide) of $33.3 million -- -- Adult patients with acquired
Rhythm Pharmaceuticals reported robust financial results for Q3 2024 with net revenue from IMCIVREE reaching $33.3 million, up from $22.5 million in the same quarter last year. The company presented positive data from an early-access program in France, showing significant BMI reductions in adult patients with acquired hypothalamic obesity. Additionally, the FDA has accepted a supplemental NDA for IMCIVREE, which could allow treatment for children as young as two, pending approval by the end of December 2024. However, the company continues to face financial challenges, reporting a net loss of $45 million for the quarter.
Read more →RYTM▲ +8.1%on this news· ran to +30% by day 3shared move
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek 2024
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek 2024
Read more →RYTMRhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome
Rhythm Pharmaceuticals and Axovia Therapeutics have announced a joint research collaboration to improve understanding and treatment of Bardet-Biedl syndrome (BBS). This partnership aims to leverage Axovia's gene therapy strategies alongside Rhythm's established expertise in the melanocortin-4 receptor pathway. The collaboration seeks to address significant challenges faced by BBS patients, particularly regarding obesity and visual impairment. Both companies are committed to advancing their research efforts to benefit individuals affected by this rare disease.
Read more →RYTMRhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024
Rhythm Pharmaceuticals announced it will report its third quarter 2024 financial results during a live conference call on November 5, 2024. This event coincides with The Obesity Society's Annual Meeting, ObesityWeek, where Rhythm will present five research posters related to its lead asset, setmelanotide. The company is committed to addressing rare neuroendocrine diseases and has seen regulatory approvals in both the U.S. and Europe for treatments associated with such conditions. This event underscores Rhythm's proactive engagement with the healthcare community and ongoing efforts in its clinical development pipeline.
Read more →RYTM▲ +8.4%on this news
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE setmelanotide in Patients as Young as 2 years old
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE setmelanotide in Patients as Young as 2 years old
Read more →RYTM▲ +8.4%on this news
Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced that CEO David Meeker will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 5, 2024. The event will be webcasted, offering investors access to insights into the company's strategies and developments. Rhythm focuses on rare neuroendocrine diseases and has gained regulatory approval for its lead asset, setmelanotide, for weight management in patients with specific genetic conditions. The company is actively advancing other therapeutics in its pipeline.
Read more →RYTMRhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update -- Second quarter 2024 net revenue from global sales of IMCIVREE (setmelanotide) of $29.1 million -- -- Dosed first patients in sup
Rhythm Pharmaceuticals reported positive financial results for Q2 2024, with IMCIVREE generating $29.1 million in global sales. The company is progressing with its global Phase 3 trial for setmelanotide in hypothalamic obesity, dosing its first patients in a Japanese cohort. Additionally, Rhythm has submitted a supplemental New Drug Application to expand the pediatric label for IMCIVREE to include patients as young as 2 years old and expects to have sufficient cash to fund operations into 2026.
Read more →RYTMRhythm Pharmaceuticals Announces European Commission Expands IMCIVREE setmelanotide Marketing Authorization to include Children as Young as 2 Years Old
Rhythm Pharmaceuticals Announces European Commission Expands IMCIVREE setmelanotide Marketing Authorization to include Children as Young as 2 Years Old
Read more →RYTMRhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
Read more →RYTMRhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
Rhythm Pharmaceuticals, Inc. announced that it will report its second quarter financial results on August 6, 2024, and provide a corporate update. David Meeker, the company's CEO, will also participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024. This announcement highlights Rhythm's ongoing commitment to addressing rare neuroendocrine diseases and indicates upcoming insights into the company’s performance and strategies.
Read more →RYTMRhythm Pharmaceuticals Announces Appointment of Alastair Garfield Ph D as Chief Scientific Officer
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield Ph D as Chief Scientific Officer
Read more →RYTMRhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
Rhythm Pharmaceuticals has received a positive recommendation from the CHMP for the marketing authorization of IMCIVREE (setmelanotide) for children aged 2 to less than 6 years with obesity due to specific genetic conditions. This marks a significant expansion of its indications to include young patients, addressing a critical gap in treatment options for severe obesity and uncontrolled hunger in this demographic. The final decision by the European Commission is expected in the second half of 2024. This opinion emphasizes the importance of early diagnosis and intervention in managing severe obesity associated with rare neuroendocrine disorders.
Read more →RYTM▲ +6.1%on this news
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
Rhythm Pharmaceuticals, Inc. has announced that its CEO, David Meeker, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. This event will be webcasted, enhancing accessibility for investors and stakeholders. Rhythm continues to focus on addressing rare neuroendocrine diseases with its lead asset, setmelanotide, which is FDA-approved for specific obesity conditions. The company's active engagement in investor relations may signify its commitment to transparency and growth opportunities.
Read more →RYTM▲ +6.1%on this news
Rhythm Pharmaceuticals Presents Patient reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
Rhythm Pharmaceuticals Presents Patient reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
Read more →RYTMRhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
Rhythm Pharmaceuticals announced that the National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for IMCIVREE (setmelanotide) for treating obesity and hyperphagia in patients with Bardet-Biedl syndrome. This guidance applies to individuals aged 6 years and older, allowing continued treatment into adulthood. The recommendation aligns with European and UK regulatory approvals, increasing access to this treatment through the National Health Service. IMCIVREE is notably significant as it addresses a previously unmet medical need for managing obesity in Bardet-Biedl syndrome patients.
Read more →RYTM▼ -10.3%on this newsshared move
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
Read more →RYTM▼ -10.3%on this newsshared move
Rhythm Pharmaceuticals Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update -- First quarter 2024 net revenue from global sales of IMCIVREE (setmelanotide) of $26.0 million -- -- On tra
Rhythm Pharmaceuticals reported its financial results for the first quarter of 2024, revealing a net revenue of $26.0 million from global sales of IMCIVREE (setmelanotide). The company is on track to submit a supplemental New Drug Application (sNDA) for treating pediatric patients aged 2 to under 6 years. A Phase 3 trial for hypothalamic obesity is progressing towards a topline data readout expected in the first half of 2025. Additionally, Rhythm secured $150 million in financing to fund its operations through 2026.
Read more →RYTMRhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
Rhythm Pharmaceuticals presented data from its Phase 3 pediatrics trial at the Pediatric Endocrine Society Annual Meeting, demonstrating that setmelanotide led to a significant reduction in BMI-Z scores and BMI in children aged 2 to younger than 6 years with specific genetic conditions. The company is on track to submit a supplementary New Drug Application to the FDA for pediatric label expansion in the first half of 2024. Additionally, two informative poster presentations were shared regarding weight management therapies in pediatric patients. The data indicate the potential for treating severe obesity in young children effectively.
Read more →RYTMRhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes Endocrinology
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes Endocrinology
Read more →RYTMRhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Rhythm Pharmaceuticals, Inc. has announced it will host a live conference call on May 7, 2024, to report its first quarter 2024 financial results and provide a corporate update. The CEO, David Meeker, will also participate in a fireside chat at the Bank of America Employee Healthcare Conference on May 14, 2024. The webcasts for both events will be available on the company's investor relations page for a limited time post-event. Rhythm continues to focus on transforming the lives of patients with rare neuroendocrine diseases through its lead product, setmelanotide.
Read more →RYTMRhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing -- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 -- BOSTON
Rhythm Pharmaceuticals has announced a successful $150 million financing through convertible preferred stock, aiming to fund its operations and clinical programs into 2026. The funding comes from existing investors, including Perceptive Advisors LLC. This capital is intended to facilitate the company's strategic goals and supports its lead product, IMCIVREE, currently available in multiple countries. The financing reinforces investor confidence in Rhythm's ongoing development plans amid anticipated milestones, particularly a pivotal trial readout scheduled for 2025.
Read more →RYTMRhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM 718 a Weekly MC4R specific Agonist
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM 718 a Weekly MC4R specific Agonist
Read more →RYTMRhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced its participation in two prominent investor conferences, including Barclays 26th Annual Global Healthcare Conference and the 23rd Annual Needham Virtual Healthcare Conference. CEO David Meeker and CFO Hunter Smith will engage in fireside chats providing updates on the company’s focus on rare neuroendocrine diseases and its lead asset, IMCIVREE (setmelanotide). The webcasts will be accessible through the Investor Relations section of the company's website.
Read more →RYTM▼ -9.7%on this news
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update -- Fourth quarter 2023 net revenue from global sales of IMCIVREE (setmelanotide) of $24.2 million -- -- Enrollment completed in 120
Rhythm Pharmaceuticals reported strong fourth quarter 2023 financial results, highlighting a net revenue of $24.2 million from IMCIVREE. The company completed enrollment in a pivotal Phase 3 clinical trial for setmelanotide, targeting hypothalamic obesity, and expects top-line data in the first half of 2025. Recent approvals for reimbursement of IMCIVREE in Spain and Italy mark important progress for the treatment of Bardet-Biedl syndrome. Additionally, the acquisition of LB54640 positions Rhythm for expanded treatment options in the obesity market.
Read more →RYTM▼ -9.7%on this news
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
Rhythm Pharmaceuticals has announced a plan to add a cohort of 12 Japanese patients to its ongoing Phase 3 clinical trial of setmelanotide for hypothalamic obesity. This decision follows discussions with Japan's Pharmaceuticals and Medical Devices Agency, aiming to support the approval of setmelanotide, which currently has no approved therapeutic options in Japan. With an estimated 5,000 to 8,000 patients affected by hypothalamic obesity in Japan, the company aims to address a significant unmet medical need. Dosing for the new cohort is expected to begin in the third quarter of 2024.
Read more →RYTMRhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
Rhythm Pharmaceuticals announced that the Italian Medicine Agency (AIFA) has approved reimbursement for their drug IMCIVREE (setmelanotide) for treating obesity and controlling hunger in patients with Bardet-Biedl syndrome (BBS). This decision allows Italian families affected by this rare neuroendocrine disease to access the only authorized treatment option in the European Union. The company is committed to expanding access to IMCIVREE across Europe, while having previously secured similar approvals for other conditions.
Read more →RYTMRhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Rhythm Pharmaceuticals has announced a conference call scheduled for February 22, 2024, to report its financial results for the fourth quarter and full year of 2023. The call will also include a corporate update from David Meeker, the company's CEO, who will participate in two upcoming conferences to discuss the company's developments. Rhythm's lead asset, setmelanotide, is FDA-approved for chronic weight management in patients with specific genetic obesity conditions, demonstrating its commitment to addressing rare neuroendocrine diseases.
Read more →RYTMRhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
Rhythm Pharmaceuticals has entered a global licensing agreement with LG Chem to acquire rights to LB54640, an investigational oral MC4R agonist currently in Phase 2 clinical trials. The drug aims to provide a targeted treatment for hyperphagia and severe obesity without the side effects of hyperpigmentation or cardiovascular issues. Rhythm plans to initiate two Phase 2 studies to evaluate the weight loss efficacy and safety of LB54640. The agreement involves substantial financial commitments from Rhythm, emphasizing the potential value of the drug in the market.
Read more →RYTMRhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
Rhythm Pharmaceuticals has completed screening for enrollment in its Phase 3 clinical trial of setmelanotide for hypothalamic obesity, anticipating top-line results in early 2025. The company reported positive news with a reimbursement decision from Spanish authorities for IMCIVREE, aiding access for patients with rare conditions. Additionally, the FDA accepted the IND application for RM-718, a new treatment that aims to improve patient outcomes in obesity management. Overall, these updates underscore Rhythm's commitment to advancing treatment options for individuals with rare neuroendocrine diseases.
Read more →RYTMRhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
Rhythm Pharmaceuticals is sponsoring the second annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) in Paris from December 13-15, 2023. The event will focus on advancing care and understanding of rare melanocortin-4 receptor (MC4R) pathway diseases, drawing approximately 150 healthcare professionals from 20 countries. Attendees will engage in discussions about scientific developments related to hyperphagia and severe obesity linked to these diseases. The meeting aims to enhance collaboration among experts in the field.
Read more →RYTMRhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
Rhythm Pharmaceuticals hosted an R&D event announcing new data on its MC4R pathway programs. The Phase 3 trial of setmelanotide in young patients showed a mean reduction in BMI-Z scores and BMI, achieving its primary endpoint. Pre-clinical data for RM-718 indicates potential in reducing body weight without cardiovascular effects. The company plans to submit regulatory applications for setmelanotide and anticipates starting Phase 1 trials for RM-718 in 2024.
Read more →RYTMRhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update -- Third quarter 2023 net revenue from global sales of IMCIVREE (setmelanotide) of $22.5 million -- -- More than 100 international p
Rhythm Pharmaceuticals reported strong financial results for Q3 2023, with $22.5 million in net revenue from IMCIVREE (setmelanotide). The company highlighted a promising 25.5% mean BMI reduction in patients with hypothalamic obesity after one year of treatment. Rhythm is expanding access to its treatments internationally, with positive reimbursement developments in France and Canada. Additionally, the company plans to share updates on its R&D programs at an investor event scheduled for December 6, 2023.
Read more →RYTMRhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE (setmelanotide)
Rhythm Pharmaceuticals announced that CADTH has recommended the reimbursement of IMCIVREE (setmelanotide) for weight management in adults and pediatric patients with Bardet-Biedl syndrome (BBS). This recommendation is based on positive results from a Phase 3 trial demonstrating meaningful clinical benefits in reducing weight-related parameters. IMCIVREE is the first therapy specifically targeting obesity related to BBS, underscoring its importance in addressing the unmet needs of these patients. The recommendation is expected to provide significant help to those suffering from the severe obesity and hyperphagia associated with BBS.
Read more →RYTMRhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
Rhythm Pharmaceuticals announced the scheduled release of its third quarter 2023 financial results in a conference call on November 7, 2023. CEO David Meeker will also participate in a fireside chat at the Stifel Healthcare Conference on November 15, 2023. The company focuses on therapies for hyperphagia and severe obesity related to rare MC4R pathway diseases, with their leading product IMCIVREE approved by the FDA and regulatory authorities in Europe.
Read more →RYTMRhythm Pharmaceuticals Presents Data from its Long term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Y
Rhythm Pharmaceuticals Presents Data from its Long term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Y
Read more →RYTMRhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society s Annual Meeting at ObesityWeek
Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society s Annual Meeting at ObesityWeek
Read more →RYTMRhythm Pharmaceuticals Presents New Data at ESPE 2023
Rhythm Pharmaceuticals presented four oral presentations at the ESPE 2023 meeting, focusing on their ongoing research on obesity and the impact of their drug setmelanotide. Noteworthy findings highlighted genetic variants linked with severe obesity, with a significant percentage of patients identified carrying relevant mutations. The company's commitment to advancing treatment for hyperphagia and severe obesity was underscored by their participation in the event. Potential future risks associated with setmelanotide's regulatory approvals and clinical outcomes were also acknowledged.
Read more →RYTMRhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals has announced that the European Medicines Agency (EMA) granted orphan drug designation for setmelanotide, intended for the treatment of acquired hypothalamic obesity. This condition arises from damage to the hypothalamus, leading to extreme obesity without effective treatment options. The designation reflects the critical unmet medical need for this patient population, with an estimated 3,500 to 10,000 individuals affected in select European countries. The company is currently conducting a Phase 3 clinical trial and anticipates completing patient enrollment by the end of 2023.
Read more →RYTMRhythm Pharmaceuticals Announces Update to September Conference Participation
Rhythm Pharmaceuticals has updated its September conference calendar, cancelling participation in the H.C. Wainwright 25th Annual Global Investment Conference due to travel conflicts. However, CEO David Meeker will still present at the Morgan Stanley 21st Annual Global Healthcare Conference. The company continues its focus on conditions related to the MC4R pathway, with its lead asset, setmelanotide, demonstrating regulatory support across several regions. There are critical discussions surrounding the safety and efficacy of their treatments.
Read more →RYTMRhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome
Rhythm Pharmaceuticals announced the approval of a new ICD-10 diagnosis code for Bardet-Biedl Syndrome, effective October 1, 2023. This code aims to improve the identification and care of patients suffering from this rare genetic disease, which had previously been reported under a more generic code. The new code is particularly significant for families and healthcare providers, facilitating access to enhanced care practices. The company believes this step marks a pivotal advancement in the management and understanding of BBS.
Read more →RYTMRhythm Pharmaceuticals to Present at Investor Conferences in September
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced its participation in three upcoming investor conferences in September 2023. The CEO, Dr. David Meeker, will present at the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference, while the CFO, Hunter Smith, will update investors at the HW Wainwright Global Investment Conference. These presentations will discuss the company's advancements and its lead asset, setmelanotide, which is approved for treating obesity linked to specific genetic conditions. The company will also provide live webcasts for each event on its investor relations website.
Read more →RYTMRhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France
Rhythm Pharmaceuticals has received pre-marketing early access authorization in France for setmelanotide, a treatment for patients with hypothalamic obesity. This designation allows patients to receive the drug before European regulatory approval, addressing a serious unmet medical need. The treatment has already been available for Bardet-Biedl syndrome since July 2022. Rhythm anticipates reimbursement for patients under this program, enhancing access to the therapy.
Read more →RYTM▲ +27.5%on this newsshared move
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update -- Second quarter 2023 net revenue of $19.2 million from global sales of IMCIVREE (setmelanotide) -- -- Strong U.S. commercial prog
Rhythm Pharmaceuticals reported a second quarter 2023 net revenue of $19.2 million from IMCIVREE global sales, indicating strong commercial progress. Over 125 new prescriptions for Bardet-Biedl syndrome were written during this quarter. The company also achieved a commercial sales milestone, becoming eligible for an additional $25 million investment. Looking ahead, Rhythm plans to submit a new drug application for RM-718 by the end of the year and expects to complete enrollment in a pivotal Phase 3 trial for setmelanotide by year-end.
Read more →RYTMRhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome
Rhythm Pharmaceuticals has announced two critical publications outlining the impact of hyperphagia and obesity on patients and caregivers living with Bardet-Biedl Syndrome (BBS). The research, published in 'The Orphanet Journal of Rare Diseases', reveals that caregivers face substantial emotional and relational challenges due to the demands of managing patients with BBS. The findings emphasize the pressing need for effective therapies to alleviate the burdens associated with the condition, as hyperphagia contributes to a range of negative outcomes in both patients and caregivers. The studies involved cross-national surveys that demonstrated consistent caregiver challenges across several countries.
Read more →RYTM▲ +5.3%on this newsshared move
Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
Rhythm Pharmaceuticals, Inc. has announced its plans to host a conference call on August 1, 2023, to discuss its second quarter 2023 financial results and provide a corporate update. The company is dedicated to transforming the lives of patients with severe obesity caused by rare melanocortin-4 receptor pathway diseases. Additionally, Rhythm’s CEO, Dr. David Meeker, is scheduled to present at the Canaccord Genuity Annual Growth Conference on August 9, 2023. Investors and interested parties can access the live conference call via the company's website.
Read more →RYTM▲ +6.9%on this news
Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023
Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023
Read more →RYTMRhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
Rhythm Pharmaceuticals, Inc. will present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 14, 2023. David Meeker, the CEO, will participate in a fireside chat, which can be accessed via a live audio webcast. Rhythm's lead product, setmelanotide, is FDA approved and has a clinical program aimed at treating rare melanocortin-4 receptor pathway diseases, including hyperphagia and severe obesity. The company is focused on transforming the lives of patients with these rare diseases.
Read more →RYTMRhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE setmelanotide to Patients in Gulf Cooperation Council Countries
Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE setmelanotide to Patients in Gulf Cooperation Council Countries
Read more →RYTMRhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE Setmelanotide Injection for Weight Management in Bardet Biedl Syndrome or Genetically confirmed Biallelic POMC P
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE Setmelanotide Injection for Weight Management in Bardet Biedl Syndrome or Genetically confirmed Biallelic POMC P
Read more →RYTM▼ -7.3%on this news· ran to -17% by day 3shared move
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update -- Strong U.S. commercial progress continues for IMCIVREE (setmelanotide) with more than 300 new prescriptions for Bardet-Biedl synd
Rhythm Pharmaceuticals reported strong commercial progress for IMCIVREE (setmelanotide), with over 300 prescriptions in the U.S. following FDA approval for Bardet-Biedl syndrome. The company launched IMCIVREE in Germany, securing federal reimbursement, and dosed the first patients in a pivotal Phase 3 trial focused on hypothalamic obesity. Financial guidance for 2023 remains steady, projecting approximately $200 million to $220 million in operating expenses, and Rhythm anticipates completing enrollment for its obesity trial by Q1 2024. A conference call is scheduled to discuss these results further.
Read more →RYTMRhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
BOSTON, April 24, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor
Read more →RYTMRhythm Pharmaceuticals to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor
Read more →RYTMRhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
Read more →RYTMRhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide
- Interview-based research published in Advances in Therapy demonstrates setmelanotide improved hyperphagia and reduced body weight and obsessive focus on food – - Company also announces publication of health state utilities study in hyperphagia - BOSTON, March 27, 2023 (GLOBE
Read more →RYTM▲ +6.3%on this newsshared move
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results -- IMCIVREE U.S. launch for Bardet-Biedl syndrome (BBS) reflects strong demand with more than 200 new prescriptions received since FDA ap
Rhythm Pharmaceuticals reported encouraging financial results for Q4 and full year 2022, highlighting the strong demand for its IMCIVREE treatment following FDA approval for Bardet-Biedl syndrome (BBS). The company has seen over 200 new prescriptions in the U.S. and is set to expand globally, including entering the German market in Q2 2023. Rhythm has also initiated a pivotal Phase 3 trial for hypothalamic obesity and acquired Xinvento B.V. to enhance its pipeline for congenital hyperinsulinism. Despite progress, the company faces challenges with reimbursement negotiations and rising R&D expenses.
Read more →RYTMRhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
- Rare disease company in preclinical development for congenital hyperinsulinism - - Acquisition is strong strategic fit with Rhythm’s rare endocrinology focus and provides meaningful new development opportunity - - Expect to initiate clinical development in 2024 - BOSTON and
Read more →RYTM▼ -6.4%on this news
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (
Read more →RYTMRhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome
- Patients reported clinically meaningful improvements across multiple health-related quality of life measures following 52 weeks of treatment with setmelanotide - - Analysis published in Orphanet Journal of Rare Diseases - BOSTON, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharm
Read more →RYTM▼ -7.1%on this news
Rhythm Pharmaceuticals, Inc. All rights reserved. January 2023 Rhythm Pharmaceuticals Transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare MC4R pathway diseases
Rhythm Pharmaceuticals has made significant strides with the launch of IMCIVREE, now FDA and EC approved for Bardet-Biedl syndrome. The company reported a strong start in the U.S. market and has expanded its addressable patient population through a comprehensive clinical development program. In 2022, Rhythm achieved multiple milestones, including successful trial results and international market access. However, they face risks related to regulatory approvals, trial outcomes, and economic conditions that could impact their future progress.
Read more →RYTMRhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (
Read more →RYTM▼ -9%on this news
Rhythm Pharmaceuticals Announces IMCIVREE setmelanotide Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet Biedl Syndrome
Rhythm Pharmaceuticals Announces IMCIVREE setmelanotide Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet Biedl Syndrome
Read more →RYTMRhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update -- U.S. launch of IMCIVREE (setmelanotide) for Bardet-Biedl Syndrome progresses with strong demand with more than 120 prescriptions
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update -- U.S. launch of IMCIVREE (setmelanotide) for Bardet-Biedl Syndrome progresses with strong demand with more than 120 prescriptions since FDA approval - -- EC authorization for IMCIVREE ex
Read more →RYTMRhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology
-- Previously disclosed data demonstrated statistically significant and clinically meaningful reductions in weight and hunger in patients with Bardet-Biedl syndrome -- BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage bioph
Read more →RYTM▲ +6.2%on this newsshared move
Rhythm Pharmaceuticals Announces 11 Presentations at The Obesity Society’s Annual Meeting at ObesityWeek
-- Analyses of Clinical Registry Investigating Bardet-Biedl Syndrome (CRIBBS) in children with BBS showed a significant positive correlation between degree of hyperphagia and body mass index (BMI) -- -- 84% of patients with BBS in Phase 3 clinical trial showed clinical benefit o
Read more →RYTM▼ -12.5%on this newsshared move
Rhythm Pharmaceuticals Presents Data from Phase 2 and Long term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek and Plans to Init
Rhythm Pharmaceuticals Presents Data from Phase 2 and Long term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek and Plans to Init
Read more →RYTMRhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (
Read more →RYTMRhythm Pharmaceuticals to Present Full Data from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity at ObesityWeek 2022
-- Rhythm to review data on webcast conference call on November 2, 2022 at 8:30 a.m. ET – -- Rhythm to report 3Q 2022 earnings on November 8, 2022 at 8:00 a.m. ET -- BOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopha
Read more →RYTMRhythm Pharmaceuticals Convenes Inaugural International Meeting on Pathway-Related Obesity: Vision of Excellence (IMPROVE) 2022
-- Approximately 100 European health care professionals invited to discuss recent scientific developments in rare pathway-related obesities -- -- Rhythm presents analysis of Phase 2 Basket Study evaluating setmelanotide in patients with obesity and MC4R variants -- BOSTON, Oct.
Read more →RYTMRhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development
BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (
Read more →RYTM▼ -10.4%on this news
Rhythm Pharmaceuticals Announces Publication of Children’s Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)
-- Book developed in collaboration with the Bardet-Biedl Syndrome Foundation -- -- BBS Global Day on Sept. 24 coordinated by BBS International -- BOSTON, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company
Read more →RYTMRhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022
-- CARE-BBS multi-country survey of 242 caregivers of individuals with Bardet-Biedl syndrome (BBS) provides extensive details on impact of hyperphagia and obesity -- -- New analyses of Phase 3 data showed setmelanotide achieved substantial weight loss benefit in adolescent and p
Read more →RYTMRhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering
BOSTON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-
Read more →RYTM▼ -24.4%on this newsshared move
Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering
BOSTON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-
Read more →RYTM▲ +24.4%on this newsshared move
Rhythm Pharmaceuticals Inc Announces Proposed Public Offering
Rhythm Pharmaceuticals Inc Announces Proposed Public Offering
Read more →RYTM▼ -14%on this newsshared move
Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Granted Marketing Authorization by European Commission for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
-- Setmelanotide now FDA-approved and EC-authorized for Bardet-Biedl syndrome (BBS) -- -- EC authorization for BBS makes Rhythm eligible to receive second $37.5M tranche under Revenue Interest Agreement with HealthCare Royalty -- -- Health Canada grants Priority Review status f
Read more →RYTM▲ +23.7%on this news· ran to +49% by day 3shared move
Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (
Read more →RYTM▲ +13.8%on this news· ran to +63% by day 3shared move
Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update -- Received FDA approval for IMCIVREE (setmelanotide) as the first-ever therapy for patients with Bardet-Biedl syndrome -- -- U.S.
Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update -- Received FDA approval for IMCIVREE (setmelanotide) as the first-ever therapy for patients with Bardet-Biedl syndrome -- -- U.S. launch off to a strong start with more than 50 IMCIVREE
Read more →RYTM▲ +14.5%on this newsshared move
Rhythm Pharmaceuticals to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (
Read more →RYTM▼ -10.8%on this news· ran to -22% by day 1
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼ IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome
-- European Commission decision anticipated in fourth quarter of 2022 -- BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living wi
Read more →RYTM▲ +24.9%on this news· ran to +39% by day 1shared move
Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France
BOSTON, July 20, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (
Read more →RYTM▲ +42.2%on this news· ran to +113% by day 3
Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity
Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity
Read more →RYTM▲ +13.6%on this news
Rhythm Pharmaceuticals Announces that European Commission Authorized Variation for IMCIVREE (setmelanotide) to Allow for Dosing in Patients with POMC or LEPR deficiency with Renal Impairment
BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that the European Commission (EC) this we
Read more →RYTM▲ +13.6%on this news
Rhythm Pharmaceuticals Launches IMCIVREE setmelanotide in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency
Rhythm Pharmaceuticals Launches IMCIVREE setmelanotide in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency
Read more →RYTM▲ +13%on this news· ran to +38% by day 3shared move
Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million
BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it has entered into a Rev
Read more →RYTM▲ +13%on this news· ran to +38% by day 3shared move
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE setmelanotide for Use in Patients with Bardet Biedl Syndrome
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE setmelanotide for Use in Patients with Bardet Biedl Syndrome
Read more →RYTM▼ -12.4%on this newsshared move
Rhythm Pharmaceuticals Presents New Data from Long-term Extension Trial Evaluating Setmelanotide in Bardet-Biedl Syndrome or POMC or LEPR Deficiency Obesity at ENDO 2022
-- Sustained weight loss observed following 18 to 36 months on therapy -- -- Setmelanotide shown to be well-tolerated for up to three years of treatment -- -- Data support continued efficacy and long-term use of setmelanotide in patients with BBS or POMC or LEPR deficiency obes
Read more →RYTM▼ -12.4%on this newsshared move
Rhythm Pharmaceuticals Presents Initial Data from Long-term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022
-- Continued reductions in BMI observed following one year of setmelanotide treatment in patients with SH2B1 or SRC1 deficiency obesities or POMC or LEPR insufficiency obesities (heterozygous) -- -- Long-term reductions in BMI support probability of success in ongoing pivotal Ph
Read more →RYTM▼ -10.1%on this news· ran to -39% by day 3shared move
Rhythm Pharmaceuticals to Present at BofA Securities 2022 Healthcare Conference
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, Chief Exec
Read more →RYTMRhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update -- Patient identification and physician engagement ongoing in preparation for U.S. commercial launch in June 2022 in BBS and Alstr m
Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update -- Patient identification and physician engagement ongoing in preparation for U.S. commercial launch in June 2022 in BBS and Alstr m syndrome, pending FDA approval -- -- First commercial p
Read more →RYTMRhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting
-- New data show setmelanotide treatment led to clinically meaningful improvements in lipid parameters, without affecting blood pressure or heart rate in patients with BBS -- -- Additional posters include data from pediatric and adolescent patients enrolled in Phase 3 trial in B
Read more →RYTM▼ -5.8%on this news· ran to -22% by day 3
Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call
Read more →RYTM▼ -16.3%on this newsshared move
Rhythm Pharmaceuticals, Inc. All rights reserved. April 2022 Rhythm Pharmaceuticals Targeting MC4R pathway and transforming the care of patients with rare genetic diseases of obesity 2 This presentation contains certain
2 This presentation contains certain forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and that involve risks and uncertainties, including without limitation statements regarding the potential, safety, efficacy, and regulator
Read more →RYTM▼ -16.3%on this newsshared move
Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity
– Phase 3 EMANATE trial to focus on rare patient populations with highest likelihood for success – – First patient enrolled in EMANATE – – Ongoing Phase 2 DAYBREAK trial to focus initially on 10 genes with strongest relevance to the MC4R pathway – – Trial and other program cha
Read more →RYTM▲ +11.4%on this news· ran to +22% by day 3
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results -- Preparations continue for U.S. commercial launch in June 2022 in BBS and Alstr m syndrome, pending FDA approval -- -- First commercial
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results -- Preparations continue for U.S. commercial launch in June 2022 in BBS and Alstr m syndrome, pending FDA approval -- sales of IMCIVREE in Germany and France expected in 2Q2022 - -- Enrollment
Read more →RYTM▲ +11.4%on this news· ran to +22% by day 3
Rhythm Pharmaceuticals to Present at Cowen Co 42nd Annual Health Care Conference
Rhythm Pharmaceuticals to Present at Cowen Co 42nd Annual Health Care Conference
Read more →RYTMRhythm Pharmaceuticals Announces Promotions within its Executive Leadership Team
BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced the promotions of Joe Shulman to Chief Te
Read more →RYTMRhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 1, 2022
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call
Read more →RYTMRhythm Pharmaceuticals Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)
-- Patients with BBS achieved deepened and sustained weight loss at 24 months on setmelanotide therapy -- -- Company to provide update on U.S. BBS commercial readiness during virtual event today at 4 p.m. ET -- BOSTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, I
Read more →RYTM▼ -5.7%on this news
Rhythm Pharmaceuticals to Host Virtual Bardet-Biedl Syndrome (BBS) Event on February 16
-- Key opinion leaders and patient caregiver to discuss patient experience -- -- Company to provide update on U.S. BBS commercial readiness during event for investors and analysts -- -- Prescription Drug User Fee Act (PDUFA) goal date for setmelanotide for patients with BBS of
Read more →RYTMRhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity
Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity
Read more →RYTMRhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in China
-- RareStone to seek marketing authorization for IMCIVREE to treat obesity due to biallelic POMC, PCSK1 and LEPR deficiencies and Bardet-Biedl and Alström syndromes in mainland China, Hong Kong and Macau -- -- Rhythm to receive $12 million upfront in cash and equity, up to $63.5
Read more →RYTMRhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE setmelanotide for Patients with Bardet Biedl Syndro
Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE setmelanotide for Patients with Bardet Biedl Syndro
Read more →RYTMRhythm Pharmaceuticals to Present at Stifel 2021 Virtual Healthcare Conference
BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President an
Read more →RYTM▲ +6.6%on this news
Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results -- U.S. and EU regulatory filings submitted for IMCIVREE (setmelanotide) for treatment of Bardet-Biedl and Alstr m syndromes; launch preparations underw
Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results -- U.S. and EU regulatory filings submitted for IMCIVREE (setmelanotide) for treatment of Bardet-Biedl and Alstr m syndromes; launch preparations underway -- -- Delivered a total of 22 presentations at three
Read more →RYTM▲ +5.1%on this news· ran to +17% by day 3shared move
Rhythm Pharmaceuticals Presents First ever Data Showing Improvements in Health related Quality of Life for Patients Living with Bardet Biedl Syndrome at ObesityWeek 2021
Rhythm Pharmaceuticals Presents First ever Data Showing Improvements in Health related Quality of Life for Patients Living with Bardet Biedl Syndrome at ObesityWeek 2021
Read more →RYTMRhythm Pharmaceuticals to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call
Read more →RYTMRhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity Genetic Testing Program
-- New data in patients with POMC or LEPR deficiency obesity show setmelanotide led to clinically meaningful improvements in health related quality of life measures and hunger -- -- Updated results from Uncovering Rare Obesity® testing program suggest up to 64.5 percent of indiv
Read more →RYTMRhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting
-- New subgroup analysis of Phase 3 data show setmelanotide achieved statistically significant weight loss and hunger reduction compared with placebo at 14 weeks in patients with Bardet-Biedl syndrome -- -- Efficacy results from complete topline analyses of Rhythm’s Phase 2 Bask
Read more →RYTMRhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE setmelanotide in Great Britain
Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE setmelanotide in Great Britain
Read more →RYTMRhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE (setmelanotide) for the treatment of obesity and control of hunger in Bardet-Biedl and Alstr m Syndromes
BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it has completed its supplemental New
Read more →RYTMRhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome
BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced an Expanded Access Program (EAP) for set
Read more →RYTMRhythm Pharmaceuticals Announces CMO Transition
-- Linda Shapiro Manning, M.D., Ph.D., promoted to Chief Medical Officer, effective Sept. 10 -- -- CMO Murray Stewart, M.D., to transition to Senior Medical Advisor -- BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical co
Read more →RYTMRhythm Pharmaceuticals to Present at Morgan Stanley 19th Annual Global Healthcare Conference
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President a
Read more →RYTMRhythm Pharmaceuticals to Present at the 59th Annual ESPE Meeting
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will present data from multiple c
Read more →RYTMRhythm Pharmaceuticals to Present at 2021 Canaccord Genuity 41st Annual Growth Conference
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President an
Read more →RYTMRhythm Pharmaceuticals Reports Second Quarter 2021 Financial Results -- Received European Commission authorization of IMCIVREE for treatment of obesity and control of hunger associated with POMC, PCSK1 and LEPR deficienc
Rhythm Pharmaceuticals Reports Second Quarter 2021 Financial Results -- Received European Commission authorization of IMCIVREE for treatment of obesity and control of hunger associated with POMC, PCSK1 and LEPR deficiencies - -- Setmelanotide selected for evaluation as a "Hi
Read more →RYTMRhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseas
Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseas
Read more →RYTM▼ -6.3%on this newsshared move
Rhythm Pharmaceuticals Announces Senior Leadership Additions
-- Pamela Cramer appointed Chief Human Resources Officer -- -- Linda Shapiro Manning, M.D., Ph.D., appointed Senior Vice President, Clinical -- BOSTON, July 29, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company co
Read more →RYTMRhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl Syndrome
BOSTON, July 28, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced a collaborative research agreement with t
Read more →RYTMRhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
BOSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it will host a live conference call and
Read more →RYTMRhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE setmelanotide for the Treatment of Obesity and Control of Hunger Associated with POMC PCSK1 and LEPR
Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE setmelanotide for the Treatment of Obesity and Control of Hunger Associated with POMC PCSK1 and LEPR
Read more →RYTMRhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel
BOSTON and PETACH TIKVA, Israel, July 22, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, and Medison Pharma, a leading co
Read more →RYTMRhythm Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
BOSTON, May 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and
Read more →RYTMRhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency
BOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that the European Medicines Agency’s (EMA)
Read more →RYTMRhythm Pharmaceuticals to Present at BofA Securities 2021 Virtual Health Care Conference
BOSTON, May 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Ch
Read more →RYTMRhythm Pharmaceuticals Reports First Quarter 2021 Financial Results -- First U.S. commercial sales of IMCIVREE (setmelanotide) completed late in first quarter - -- Late-breaking data presentations at ENDO 2021 demonstrat
Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results -- First U.S. commercial sales of IMCIVREE (setmelanotide) completed late in first quarter - -- Late-breaking data presentations at ENDO 2021 demonstrated continued weight loss with setmelanotide at up to ni
Read more →RYTMRhythm Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President a
Read more →RYTMRhythm Pharmaceuticals Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss at Up to Nine Months in Patients with HET Obesity on Setmelanotide at ENDO 2021
-- Responders with HET obesity achieved mean weight loss of greater than 12 percent at nine months on setmelanotide therapy -- -- Additional poster presentations include Phase 3 data in Bardet-Biedl and Alström syndromes and analyses of adverse events in Phase 2 and Phase 3 stud
Read more →RYTMRhythm Pharmaceuticals Announces Late Breaking Data Presentations at ENDO 2021
Rhythm Pharmaceuticals Announces Late Breaking Data Presentations at ENDO 2021
Read more →RYTMRhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results -- Received FDA approval of IMCIVREE (setmelanotide), the first-ever therapy for chronic weight management in patients with obesity due t
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results FDA approval of IMCIVREE (setmelanotide), the first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency -- positive topline data from Phase
Read more →RYTMRhythm Pharmaceuticals to Present at Cowen & Co. 41st Annual Health Care Conference
BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., President and Chief
Read more →RYTMRhythm Pharmaceuticals, Inc. Announces Closing of $172.5 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
BOSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced the closing of its public offering of 5,750,
Read more →RYTMRhythm Pharmaceuticals Inc Announces Pricing of Public Offering
Rhythm Pharmaceuticals Inc Announces Pricing of Public Offering
Read more →RYTMRhythm Pharmaceuticals, Inc. All rights reserved. February 2021 Rhythm Pharmaceuticals Targeting MC4R pathway and transforming the care of patients with rare genetic diseases of obesity 2 This presentation contains certa
2 This presentation contains certain statements that are forward - looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including without
Read more →RYTMRhythm Pharmaceuticals, Inc. Announces Proposed Public Offering
BOSTON, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced a proposed public offering of $150 million o
Read more →RYTMRhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency related Obesities
Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency related Obesities
Read more →RYTMRhythm Pharmaceuticals to Provide Update on Phase 2 Basket Study and Genetic Sequencing Efforts
BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it plans to host a virtual event on Tues
Read more →RYTMRhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100M
BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it has entered into a definitive agreeme
Read more →RYTMRhythm Pharmaceuticals Announces Appointments of Camille L Bedrosian M D and Lynn Tetrault J D to its Board of Directors
Rhythm Pharmaceuticals Announces Appointments of Camille L Bedrosian M D and Lynn Tetrault J D to its Board of Directors
Read more →RYTMRhythm Pharmaceuticals Announces FDA Approval of IMCIVREE setmelanotide as First ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC PCSK1 or LEPR Defic
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE setmelanotide as First ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC PCSK1 or LEPR Defic
Read more →RYTMRhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek 2020
Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek 2020
Read more →RYTMRhythm Pharmaceuticals Reports Third Quarter 2020 Financial Results -- NDA for setmelanotide for POMC and LEPR deficiency obesities under review, with PDUFA goal date of
Rhythm Pharmaceuticals Reports Third Quarter 2020 Financial Results -- NDA for setmelanotide for POMC and LEPR deficiency obesities under review, with PDUFA goal date of November 27, 2020 -- Jennifer Chien and Yann Mazabraud to co-lead global integrated commercial strategies
Read more →RYTMRhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology
BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, announced today that results from two pivotal Pha
Read more →RYTMRhythm Pharmaceuticals Appoints Jennifer Chien as Executive Vice President, Head of North America
BOSTON, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Jennifer Chien has been appo
Read more →RYTMRhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International
– Company announces organizational changes designed to accelerate global strategy – BOSTON, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment o
Read more →RYTMRhythm Pharmaceuticals to Present Virtually at Canaccord Genuity 40th Annual Growth Conference
BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that David Meeker, M.D., Chair,
Read more →RYTMRhythm Pharmaceuticals Reports Second Quarter 2020 Financial Results -- Appointed David Meeker, M.D., as President and Chief Executive Officer - -- FDA granted rare pediatric disease designations for setmelanotide for th
Rhythm Pharmaceuticals Reports Second Quarter 2020 Financial Results Appointed David Meeker, M.D., as President and Chief Executive Officer - FDA granted rare pediatric disease designations for setmelanotide for the treatment of POMC and LEPR deficiency obesities -- Submitted
Read more →RYTMRhythm Pharmaceuticals Announces Appointment of Joseph Shulman as Senior Vice President of Technical Operations
BOSTON, July 27, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced the appointment of Joseph Shulman
Read more →RYTMRhythm Pharmaceuticals Announces Appointment of David Meeker M D as Chief Executive Officer
Rhythm Pharmaceuticals Announces Appointment of David Meeker M D as Chief Executive Officer
Read more →RYTMRhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolism
-- Study demonstrated that treatment with setmelanotide reduced body weight and hunger in individuals living with Bardet-Biedl syndrome -- BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at develo
Read more →RYTMRhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U S Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities
Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U S Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities
Read more →RYTMRhythm Pharmaceuticals Announces Submission of Marketing Authorization Application to the European Medicines Agency for Setmelanotide in POMC and LEPR Deficiency Obesities
-- Company also announces positive data from eight supplemental patients, including four pediatric patients, enrolled in pivotal Phase 3 clinical trials; all achieved primary endpoint of 10 percent weight loss -- -- Setmelanotide was well-tolerated in long-term extension study w
Read more →RYTMRhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers
-- Once-weekly formulation of setmelanotide achieved weight loss efficacy comparable to daily-dosing formulation – -- Both weekly and daily formulations of setmelanotide were observed to be safe and well-tolerated – -- Pharmacokinetics analysis showed weekly formulation of setm
Read more →RYTMRhythm Pharmaceuticals to Present Virtually at Upcoming Investor Conference in June
BOSTON, May 26, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that company management will part
Read more →RYTMRhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities
Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities
Read more →RYTMRhythm Pharmaceuticals to Present Virtually at 2020 BofA Securities Health Care Conference
BOSTON, May 05, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Hunter Smith, Interim Chief
Read more →RYTMRhythm Pharmaceuticals Reports First Quarter 2020 Financial Results
-- Completed rolling NDA submission to FDA for setmelanotide in POMC and LEPR deficiency obesities; on track to submit MAA to EMA in the second quarter of 2020 – -- Received Orphan Drug Designation from FDA for setmelanotide for the treatment of Alström syndrome -- -- Continues
Read more →RYTMRhythm Pharmaceuticals to Present Virtually at Needham & Co. 19th Annual Healthcare Conference
BOSTON, April 07, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Hunter Smith, Interim Chie
Read more →RYTMRhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U S Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities
Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U S Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities
Read more →RYTMRhythm Pharmaceuticals Provides Updates on Leadership Transition and Business Operations
Hunter Smith, Chief Financial Officer, appointed Interim Chief Executive Officer following completion of NDA submission to FDA Precautionary measures in place to mitigate impact of COVID-19 on clinical programs BOSTON, March 30, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals,
Read more →RYTMRhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results -- On track to complete rolling NDA submission to the FDA for setmelanotide in POMC and LEPR deficiency obesities in the first quarter of
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results to complete rolling NDA submission to the FDA for setmelanotide in POMC and LEPR deficiency obesities in the first quarter of 2020 drug designation by the European Medicines Agency for setmelano
Read more →RYTMRhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference
BOSTON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Murray Stewart, M.D., Chief
Read more →RYTMRhythm Pharmaceuticals, Inc. All rights reserved. Rhythm Pharmaceuticals, Inc. All rights reserved. January 2020 Rhythm Pharmaceuticals Targeting MC4R pathway and transforming the care of patients with rare genetic disor
2 This presentation contains certain statements that are forward - looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statemen
Read more →RYTMRhythm Pharmaceuticals Announces Leadership Transition Keith Gottesdiener, M.D. to Step Down as Chief Executive Officer Following NDA Submission for Setmelanotide in POMC and LEPR Deficiency Obesities Expected in the Fir
Rhythm Pharmaceuticals Announces Leadership Keith Gottesdiener, M.D. to Step Down as Chief Executive Officer Following NDA Submission for Setmelanotide in POMC and LEPR Deficiency Obesities Expected in the First Board Forms Search Committee to Assist in Identifying Successor
Read more →RYTMRhythm Pharmaceuticals to Present at Stifel 2019 Healthcare Conference
BOSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Hunter Smith, Chief Financial Officer o
Read more →RYTMRhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019 Data show treatment effect of setmelanotide on additional secondary endpo
Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019 Data show treatment effect of setmelanotide on additional secondary endpoints, including body mass index Additional safety analyses
Read more →RYTMRhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results Announced Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities Added Four New MC
Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results Announced Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities Added Four New MC4R Pathway Obesity Indications to Phase 2 Basket Study and
Read more →RYTMRhythm Pharmaceuticals Announces Late Breaking Data Presentations at ObesityWeek 2019
Rhythm Pharmaceuticals Announces Late Breaking Data Presentations at ObesityWeek 2019
Read more →RYTMRhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
BOSTON, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the closing of its public off
Read more →RYTMRhythm Pharmaceuticals, Inc. Announces Proposed Public Offering Boston, MA
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering Boston, MA October 15, 2019 Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obe
Read more →RYTMRhythm Pharmaceuticals Provides Update on Research and Development Programs Four new MC4R pathway obesity indications added to Phase 2 Basket Study and enrolling patients Genetic sequencing of 13,567 individuals with sev
Rhythm Pharmaceuticals Provides Update on Research and Development Programs Four new MC4R pathway obesity indications added to Phase 2 Basket Study and enrolling patients Genetic sequencing of 13,567 individuals with severe obesity yields 11.7 percent (1,584 individuals) who ha
Read more →RYTMRhythm Pharmaceuticals to Provide an Update on Genetic Sequencing Efforts and Expansion of Phase 2 Basket Study with Four Additional Rare MC4R Pathway driven Disorders
Rhythm Pharmaceuticals to Provide an Update on Genetic Sequencing Efforts and Expansion of Phase 2 Basket Study with Four Additional Rare MC4R Pathway driven Disorders
Read more →RYTMRhythm Pharmaceuticals to Present at Upcoming Investor Conferences in September
BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that company management will participate in
Read more →RYTMRhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities
-- Both studies met primary and all key secondary endpoints with statistically significant and clinically meaningful results in reductions of weight and hunger -- -- Rhythm on track to complete rolling NDA submission to the FDA for both POMC and LEPR deficiency obesities in 4Q19
Read more →RYTMUNDER EMBARGO UNTIL WEDNESDAY AUGUST 7 2019 AT 7:01AM EDT Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities Both
UNDER EMBARGO UNTIL WEDNESDAY AUGUST 7 2019 AT 7:01AM EDT Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities Both studies met primary and all key secondary endpoints with
Read more →RYTMRhythm Pharmaceuticals Reports Second Quarter 2019 Financial Results Launched Uncovering Rare Obesity to facilitate diagnosis of rare genetic disorders of obesity Announced positive opinion by EMA on Orphan Drug Designat
Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial Results Launched Uncovering Rare Obesity to facilitate diagnosis of rare genetic disorders of obesity Announced positive opinion by EMA on Orphan Drug Designation for setmelanotide for the treatment of patients with B
Read more →RYTMRhythm Pharmaceuticals Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for Setmelanotide for the Treatment of Bardet-Biedl Syndrome Boston, MA
Rhythm Pharmaceuticals Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for Setmelanotide for the Treatment of Bardet-Biedl Syndrome Boston, MA July 29, 2019 - Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused o
Read more →RYTMRhythm Pharmaceuticals Announces Appointment of Stuart Arbuckle to its Board of Directors Boston, MA
Rhythm Pharmaceuticals Announces Appointment of Stuart Arbuckle to its Board of Directors Boston, MA July 24, 2019 - Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare
Read more →RYTMRhythm Pharmaceuticals Launches Free Genetic Testing Program for Rare Genetic Disorders of Obesity
-- Uncovering Rare Obesity program may help determine underlying cause of severe obesity -- -- Program increases access to genetic testing to improve diagnosis of rare genetic disorders of obesity -- BOSTON, July 17, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq
Read more →RYTMRhythm Pharmaceuticals Announces Election of Jennifer Good to its Board of Directors
BOSTON, June 19, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the election of Jennifer Good
Read more →RYTMRhythm Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
BOSTON, May 30, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D.,
Read more →RYTMRhythm Pharmaceuticals to Present at Bank of America Merrill Lynch 2019 Health Care Conference
BOSTON, May 07, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D.,
Read more →RYTMRhythm Pharmaceuticals Reports First Quarter 2019 Financial Results - Announced updated clinical data from Phase 2 basket study of setmelanotide in MC4R pathway heterozygous (HET) obesity, demonstrating consistent weight
Rhythm Pharmaceuticals Reports First Quarter 2019 Financial Results - Announced updated clinical data from Phase 2 basket study of setmelanotide in MC4R pathway heterozygous (HET) obesity, demonstrating consistent weight and hunger responses in patients with high-impact loss-of-
Read more →RYTMRhythm Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference
BOSTON, April 02, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that company management will
Read more →RYTMRhythm Pharmaceuticals Announces Promising Clinical Data in MC4R Pathway Heterozygous Obesity and Strategy for Further Development Stratifying Enrollment of MC4R Pathway Heterozygous (HET) Patients in Phase 2 Basket Stud
Rhythm Pharmaceuticals Announces Promising Clinical Data in MC4R Pathway Heterozygous Obesity and Strategy for Further Development Stratifying Enrollment of MC4R Pathway Heterozygous (HET) Patients in Phase 2 Basket Study Based on Loss-of-Function (LOF) Variants Preliminary Dat
Read more →RYTMRhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results Boston, MA
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results Boston, MA March 8, 2019 Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic
Read more →RYTMRhythm Pharmaceuticals to Present at Cowen & Co. 39th Annual Health Care Conference
BOSTON, March 04, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D
Read more →RYTMRhythm Pharmaceuticals to Outline Expected 2019 Milestones and Review Updated Clinical Data in Bardet-Biedl Syndrome at 37 th Annual J.P. Morgan Healthcare Conference - Updated clinical data from Phase 2 basket studies e
Rhythm Pharmaceuticals to Outline Expected 2019 Milestones and Review Updated Clinical Data in Bardet-Biedl Syndrome at 37th Annual J.P. Morgan Healthcare Conference - Updated clinical data from Phase 2 basket studies evaluating setmelanotide in Bardet-Biedl Syndrome (BBS) show
Read more →RYTMRhythm Pharmaceuticals to Host Key Opinion Leader Symposium on MC4R Pathway and Patient Experience with Rare Genetic Disorders of Obesity, Including Bardet-Biedl Syndrome
BOSTON, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that it will host a key opini
Read more →RYTMManagement s Discussion and Analysis of Financial Condition and Results of Operations The following discussion reflects the retrospective application of Accounting Standards Update (ASU) 2016-18, Statement of Cash Flows
Management s Discussion and Analysis of Financial Condition and Results of Operations The following discussion reflects the retrospective application of Accounting Standards Update (ASU) 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (ASU 2016-18), adopted on Janu
Read more →RYTMRhythm Pharmaceuticals Reports Third Quarter 2018 Financial Results Presented Updated Data from Phase 2 Basket Studies in Bardet-Biedl Syndrome (BBS) and Alstr m Syndrome at the 57 th Annual European Society for Pediatri
Rhythm Pharmaceuticals Reports Third Quarter 2018 Financial Results Presented Updated Data from Phase 2 Basket Studies in Bardet-Biedl Syndrome (BBS) and Alstr m Syndrome at the 57th Annual European Society for Pediatric Endocrinology (ESPE) Meeting Launched TEMPO Registry for
Read more →RYTMRhythm Pharmaceuticals to Present at Stifel 2018 Healthcare Conference
BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that company management will
Read more →RYTMRhythm Pharmaceuticals Appoints Murray W. Stewart, M.D., as Chief Medical Officer
BOSTON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the appointment of Murray W.
Read more →RYTMRhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of Obesity
BOSTON, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the launch of a new non-inte
Read more →RYTMRhythm Pharmaceuticals to Present at Ladenburg Thalmann 2018 Healthcare Conference
BOSTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D
Read more →RYTMRhythm Pharmaceuticals to Present at Morgan Stanley 16th Annual Global Healthcare Conference
BOSTON, Sept. 07, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D
Read more →RYTMRhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results Completed Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Pro-opiomelanocortin (POMC) and Leptin Receptor (LEPR)
Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results Completed Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Pro-opiomelanocortin (POMC) and Leptin Receptor (LEPR) Deficiency Obesity Announced New Topline Clinical Data fro
Read more →RYTMRhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity
BOSTON, July 23, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that the European Medicines A
Read more →RYTMRhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
-- Further Improvements Observed in Bardet-Biedl Syndrome Patients; Initial Proof-of-Concept Data in Alström Syndrome Demonstrates Significant Weight Loss and Decreased Hunger -- -- Rhythm Plans to Initiate Combined Pivotal Phase 3 Trial in Bardet-Biedl Syndrome and Alström Synd
Read more →RYTMRhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
BOSTON, June 14, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that it has completed enrollm
Read more →RYTMRhythm Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference
BOSTON, June 01, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D., Chief Executi
Read more →RYTMRhythm Pharmaceuticals Reports First Quarter 2018 Financial Results U.S. Food and Drug Administration (FDA) Agreed that Bardet-Biedl Syndrome (BBS) and Alstr m Syndrome are Included Under Existing Breakthrough Therapy De
Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results U.S. Food and Drug Administration (FDA) Agreed that Bardet-Biedl Syndrome (BBS) and Alstr m Syndrome are Included Under Existing Breakthrough Therapy Designation (BTD) for Setmelanotide Entered Licensing Agreem
Read more →RYTMRhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
BOSTON, May 09, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D., Chief Executiv
Read more →RYTMRhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency Obesity
Longer-term data from open label study show reductions in hyperphagia and body weight In vitro analyses advance understanding of setmelanotide’s activity at the MC4 receptor, a part of a key pathway regulating energy homeostasis and appetite BOSTON, May 09, 2018 (GLOBE NEWSWIRE
Read more →RYTMRhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi Syndrome Oral Ghrelin O-Acyltransferase (GOAT) Inhibitor Complements an
Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi Syndrome Oral Ghrelin O-Acyltransferase (GOAT) Inhibitor Complements and Expands Efforts in Prader-Willi Syndrome In Preclinical
Read more →RYTMRhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR POMC And PCSK1 Variants at ENDO 2018
Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR POMC And PCSK1 Variants at ENDO 2018
Read more →RYTMRhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results Continuing Enrollment in Pivotal Phase 3 Clinical Trial of Setmelanotide in Pro-Opiomelanocortin (POMC) Deficiency Obesity; On Track to C
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results Continuing Enrollment in Pivotal Phase 3 Clinical Trial of Setmelanotide in Pro-Opiomelanocortin (POMC) Deficiency Obesity; On Track to Complete Enrollment of 10 Patients in First Half of 2018 En
Read more →RYTMRhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March
BOSTON, March 07, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that company management will present a corp
Read more →RYTMRhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity
- Final protocol confirmed for pivotal Phase 3 clinical trial in pro-opiomelanocortin (POMC) deficiency obesity - - Setmelanotide granted Orphan Drug Designation for treatment of leptin receptor (LEPR) deficiency obesity; Opened enrollment in pivotal Phase 3 trial in LEPR - -
Read more →RYTMRhythm Pharmaceuticals Reports Third Quarter 2017 Financial Results
- Successfully Completed Upsized Initial Public Offering Raising $137.8 Million in Gross Proceeds - - Presented Preliminary Data from Phase 2 Clinical Trial of Setmelanotide in Bardet-Biedl Syndrome (BBS) at ObesityWeek - BOSTON, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Rhythm Pharmac
Read more →RYTMRhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic d
Read more →RYTMRhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome
-- Substantial Weight Loss Observed in 4 of 5 Patients -- -- Hunger Scores Improved in All 5 Treated Patients -- -- Results presented at ObesityWeek 2017 Meeting -- BOSTON, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical compan
Read more →RYTMCONFIDENTIAL Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome Substantial Weight Loss Observed in 4 of 5 Patients Hunger Scores Improved in All 5 Treated Patien
Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome Substantial Weight Loss Observed in 4 of 5 Patients Hunger Scores Improved in All 5 Treated Patients Results presented at ObesityWeek 2017 Meeting BOSTON, MA - Octobe
Read more →RYTMRhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Boston, MA
Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Boston, MA October 10, 2017 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and com
Read more →RYTMRhythm Pharmaceuticals Inc Announces Pricing of Initial Public Offering
Rhythm Pharmaceuticals Inc Announces Pricing of Initial Public Offering
Read more →Competitive Position
How RYTM ranks across every disease it competes inCompetitive Position is a premium feature
See how RYTM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial